Targeting splicing in spinal muscular atrophy

Annals of Neurology

Volumn 63, Issue 1, 2008, Pages 3-6

  Burnett, Barrington G ^a   Sumner, Charlotte J ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (N ETHYL N ISOPROPYL)AMILORIDE; CALCIUM ION; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; MESSENGER RNA PRECURSOR; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM PROTON EXCHANGE PROTEIN; SURVIVAL MOTOR NEURON PROTEIN; TRANS ACTING FACTOR;

ALTERNATIVE RNA SPLICING; ANAEROBIC GLYCOLYSIS; AUTOSOMAL RECESSIVE INHERITANCE; CHROMOSOME 5; DISEASE SEVERITY; EDITORIAL; ENHANCER REGION; HEART PROTECTION; HUMAN; INCIDENCE; LYMPHOID CELL; MOTOR NEURON DISEASE; PRIORITY JOURNAL; SILENCER ELEMENT; SPINAL MUSCULAR ATROPHY;

AMILORIDE; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; EXONS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUSCULAR ATROPHY, SPINAL; NERVE TISSUE PROTEINS; RNA SPLICING; RNA-BINDING PROTEINS;

EID: 39049154925     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.21305     Document Type: Editorial

References (19)

1. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995;80:155-165.
2. Feldkotter M, Schwarzer V, Wirth R, et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet 2002;70:358-368.
3. Lorson CL, Hahnen E, Androphy EJ, Wirth B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A 1999;96:6307-6311.
4. Monani UR, Lorson CL, Parsons DW, et al. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum Mol Genet 1999;8:1177-1183.
5. Prior TW, Swoboda KJ, Scott HD, Hejmanowski AQ. Homozygous SMN1 deletions in unaffected family members and modification of the phenotype by SMN2. Am J Med Genet A 2004;130:307-310.
6. Sumner CJ. Molecular mechanisms of spinal muscular atrophy. J Child Neurol 2007;22:979-989.
7. Yuo.
8. Cartegni L, Krainer AR. Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003;10:120-125.
9. Andreassi C, Jarecki J, Zhou J, et al. Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001;10:2841-2849.
10. Coady TH, Shababi M, Tullis GE, Lorson CL. Restoration of SMN function: delivery of a trans-splicing RNA re-directs SMN2 pre-mRNA splicing. Mol Ther 2007;15:1471-1478.
11. Borsi L, Allemanni G, Gaggero B, Zardi L. Extracellular pH controls pre-mRNA alternative splicing of tenascin-C in normal, but not in malignantly transformed, cells. Int J Cancer 1996;66:632-635.
12. Borsi L, Balza E, Gaggero B, et al. The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH. J Biol Chem 1995;270:6243-6245.
13. Mauduit C, Chatelain G, Magre S, et al. Regulation by pH of the alternative splicing of the stem cell factor pre-mRNA in the testis. J Biol Chem 1999;274:770-775.
14. Gumina RJ, Mizumura T, Beier N, et al. A new sodium/hydrogen exchange inhibitor, EMD 85131, limits infarct size in dogs when administered before or after coronary artery occlusion. J Pharmacol Exp Ther 1998;286:175-183.
15. Scholz W, Albus U, Counillon L, et al. Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovasc Res 1995;29:260-268.
16. Karmazyn M. Amiloride enhances postischemic ventricular recovery: possible role of Na+-H+ exchange. Am J Physiol 1988;255:H608-H615.
17. Theroux P, Chaitman BR, Danchin N, et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Guard during ischemia againstnecrosis (GUARDIAN) Investigators. Circulation 2000;102:3032-3038.
18. Zeymer U, Suryapranata H, Monassier JP, et al. The Na(+)/H(+) exchange inhibitor eniporide as an adjunct to early reperfusion therapy for acute myocardial infarction. Results of the evaluation of the safety and cardioprotective effects of eniporide in acute myocardial infarction (ESCAMI) trial. J Am Coll Cardiol 2001;38:1644-1650.
19. Jumaa H, Nielsen PJ. The splicing factor SRp20 modifies splicing of its own mRNA and ASF/SF2 antagonizes this regulation. Embo J 1997;16:5077-5085.